Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia.
Brandon CieniewiczEdson R A OliveiraMike SaxtonDamoun TorabiAnkit BhattaPhanidhar KukutlaAlexander ArballoZhuo YangBi YuMaria FateHongxiu NingLawrence CoreyAbhishek MaitiDaniel CoreyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
These results highlight TIM-4-L as a highly prevalent target on AML across a range of genetic classifications and novel target for T cell-based therapy in AML. Further investigations into the role of TIM-4-L in AML pathogenesis and its potential as an anti-leukemic target for clinical development are warranted.